A mouse watched YouTube. Then scientists mapped a tiny piece of its brain.
Show Caption
Hide Caption
Dire wolves extinct for 13,000 years recreated from ancient DNA
Colossal, a Texas-based biotech company, revealed that it successfully recreated extinct dire wolves.
Scientists created the largest functional map of a brain to date using a piece of a mouse's brain.
The map details the wiring that connects neurons, offering insight into brain function and organization.
Researchers believe this work could eventually lead to treatments for brain disorders like Alzheimer's, Parkinson's and schizophrenia.
Scientists have achieved a feat once believed impossible, constructing the largest functional map of a brain to date, which they believe could eventually lead to the discovery of medications for hard-to-treat brain disorders like Alzheimer's and Parkinson's disease.
Using a piece of a mouse's brain no larger than a grain of sand, scientists from across three institutions created a detailed diagram of the wiring that connects neurons as they send messages through the brain.
The project, called Machine Intelligence from Cortical Networks (MICrONS), offers unprecedented insight into the brain's function and organization that could help unlock the secrets of intelligence.
David Markowitz, a scientist who helped coordinate the project, said the data, published April 9 in the journal Nature marks 'a watershed moment for neuroscience, comparable to the Human Genome Project in their transformative potential.'
If you give a mouse YouTube
In the study, scientists looked at a small piece of the mouse's brain called the neocortex, which receives and processes visual information. It's the newest part of the brain in terms of evolution, and differentiates the brains of mammals from other animals, according to researchers.
A team of researchers at Baylor College of Medicine in Houston started by recording brain activity in a portion of the mouse's visual cortex roughly the size of a grain of salt while it watched a series of YouTube clips and movies.
Scientists at the Allen Institute, a research center in Seattle, then sliced that piece of the mouse's brain into more than 25,000 layers, each a tiny fraction of the width of a human hair, and took high resolution photos of the slices through microscopes. The material was sent to a team at Princeton University, in New Jersey, which used artificial intelligence to reconstruct the pieces in 3D.
Other scientists compared their approach to understanding a car's combustion engine.
'Just as an engine is composed of pistons, cylinders and a fuel system, the brain consists of neurons and synapses – the tiny, specialized connections at which neurons communicate,' two Harvard researchers wrote in a companion piece to the Nature article.
The data set from the research contains 84,000 neurons, 500 million synapses and neuronal wiring that could extend the length of New York's Central Park nearly one and a half times, molecular biologists Mariela Petkova and Gregor Schuhknecht wrote.
Findings from the studies have led to discoveries of new cell types, characteristics and ways to classify cells, researchers said. The achievement also puts scientists closer to their larger goal of mapping the wiring of the entire brain of a mouse.
'Inside that tiny speck is an entire architecture like an exquisite forest,' Clay Reid, a senior investigator who helped pioneer this area of study, said in a statement. 'It has all sorts of rules of connections that we knew from various parts of neuroscience, and within the reconstruction itself, we can test the old theories and hope to find new things that no one has ever seen before.'
Why it matters
Researchers view wiring diagrams as a foundational step that scientists can build on and, eventually, potentially use to find treatments for brain conditions like Alzheimer's, Parkinson's and schizophrenia.
They compare the studies to the Human Genome Project, which created the first complete map of the DNA in every human cell. The Human Genome Project has led to profound advances in drug discovery, treatments and disease screenings and helped pave the way for revolutionary gene therapies to treat certain diseases, including some cancers.
With a functional map of the brain, researchers say they now have the ability to understand the brain's form and function and have opened up new pathways to study intelligence.
Nuno da Costa, an associate investigator at the Allen Institute, described the data they collected as a 'kind of Google map' of the piece of the visual cortex.
'If you have a broken radio and you have the circuit diagram, you'll be in a better position to fix it,' he said in a statement. 'In the future, we can use this to compare the brain wiring in a healthy mouse to the brain wiring in a model of disease.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
2 hours ago
- Chicago Tribune
Column: Waukegan ravines need more action, less studies
In spring, Waukegan's ravines are filled with flowing water and after recent heavy rains a swollen Waukegan River looks, well, like an honest-to-goodness river. Which makes one wonder why the city needs yet another study on the unique ravine system. Often overlooked and undervalued, the city's ravine system and the 4.2-mile Waukegan River are natural features in an urban landscape that could eventually offer immense environmental benefits at minimal cost. The ravine network includes Bowen Park, Washington Park, Roosevelt Park, Upton Park, Powell Park and areas off Sheridan Road, north of Grand Avenue, among other locales in Waukegan. The ravines and Waukegan River have been eyed for years as home to a trail network winding across all parts of the city. The system is targeted for a new year-long study slated to begin Sept. 1 by the city, Chicago-based Great Lakes and St. Lawrence Cities Initiative and a $250,000 grant from the National Fish and Wildlife Foundation, according to a Steve Sadin front-page story in the Aug. 12 News-Sun. The aim of the Waukegan River Ravines Corridor Improvements Project is to come up with solutions to eroding ravines and overall improvement of the network. Sounds awfully similar to the aspirations of a study published in March 2024 when the city partnered with the University of Illinois-Chicago Climate and Health Institute for research and outreach around the ravines. The report, which also included input from city residents, made recommendations for future projects and research for the ecosystem. For many, Waukegan's ravines are a well-kept secret where deer and other woodland creatures are known to exist. They were areas to be played in and around. Where the occasional molting chinook salmon can be found in the fall, migrating westward in a shallow Waukegan River from Lake Michigan on its way to a futile attempt at continuing the species' life cycle. At the same time, the ravines have become junkyards, where home appliances, grocery carts, bald tires, grass clippings and autumn leaves have been dumped. Some of that has lessened as residents have become more ecologically conscious, especially along the Waukegan River which flows eastward to Lake Michigan. In the early 1990s, as Illinois allowed the operation of floating gaming venues, the rivulet was considered by one developer to house a riverboat casino. His plan was to dredge the river where it enters Lake Michigan, put a riverboat on a tether and let it drift as guests gambled. The plan sank, leaving Waukegan without a casino. That was until The Temporary opened in 2023 at the Fountain Square entertainment zone, bringing Las Vegas-quality gaming to Lake County. City officials in the past have acknowledged the ravine system. There's a Ravine Avenue on the South Side and the senior citizen housing complex of Ravine Terrace, built in 1964, on Martin Luther King Jr. Avenue. One who haunted the Waukegan River ravine and used it to get to the city's downtown library was favorite son Ray Bradbury, whose home on St. James Street was near the ravine. In 'Dandelion Wine,' Bradbury's homage to 'Green Town' — aka Waukegan — the author who went on to acclaim as one of the world's great science fiction writers, describes the '113 steps' of the 'Dandelion Trail' in the ravines 'a pit of jungle blackness' where 'all things without names lived in the huddled tree shadow.' Indeed, the UIC study determined that 'ravines are part of what makes Waukegan special.' Besides green spaces, the ravines offer flood prevention and muffle city noises, among other benefits, the study outlined. 'Developing and improving access to ravines can reduce public health care and infrastructure costs and increase property values,' the study reported. It recommended signage for access points to the ravines, along with publishing maps of the ravine system. It also recommended continuing to develop infrastructure such as walkways, railings and benches to improve access for exercise and leisure activities to boost the health and well-being of city residents, and forming a city task force specifically for the ravine network. To my knowledge, none of the UIC study proposals were followed through on. Whether Waukegan's steep-sloped ravines are considered to be gullies or washes, they are unmatched and untapped treasures. It's unusual for a city to have such unused habitats. Lake Forest has similar ravines, where deer are known to roam, behind stately homes along Deer Path Road. None of the North Shore city can offer public access and destinations like Waukegan's. The basics are there for city stakeholders to investigate and take further action. Another ravine study isn't needed to know what to do.
Business Wire
2 hours ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Yahoo
3 hours ago
- Yahoo
Cholesterol Isn't Just About Heart Health—It May Be the Missing Link In Alzheimer's, Says New Study
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that there's a link between how well you move cholesterol to the neurons in your brain and Alzheimer's disease. This factor is connected to the APOE4 genetic variant, which significantly increases your risk of developing the disease. Here's what to know and what this means for Alzheimer's research. Alzheimer's disease sparks a cascade of changes throughout the body that lead to a slew of debilitating symptoms. But there's one surprising biological change that researchers are just starting to uncover, thanks to a new study. The study, which was published in the Journal of Lipid Research, found that people with Alzheimer's disease experience a breakdown in the ability to shuttle cholesterol to the neurons in their brain, and that this symptom is linked to a certain genetic variant called APOE4, which carries a known risk for Alzheimer's. This biological discovery could potentially pave the way for a better understanding of the disease and even future disease prevention methods. Here's what you need to know about the science so far, with input from a neurologist. Meet the expert: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA. What did the researchers find? For the study, researchers analyzed the cerebrospinal fluid (the biological liquid that surrounds and cushions the brain and spinal cord) from 10 patients with Alzheimer's disease and compared it to the cerebrospinal fluid of 10 people who did not have the condition. They discovered that lipoproteins (round particles made of fat and protein) in the cerebrospinal fluid of Alzheimer's patients were less effective at delivering cholesterol to neurons, or nerve cells, which are responsible for transmitting information from the brain throughout the body. What is cholesterol? Cholesterol is an essential, waxy, fat-like molecule that your body needs for good health, according to the National Heart Lung and Blood Institute (NHLBI). Cholesterol is carried around your body by two types of lipoproteins: low-density lipoproteins (a.k.a. LDL or 'bad' cholesterol) and high-density lipoproteins (a.k.a. HDL or 'good' cholesterol). High levels of LDL cholesterol can cause a buildup of fatty deposits called plaque in your arteries, raising the risk of heart attack, stroke, and other health complications, per the NHLBI. But high levels of good HDL cholesterol may lower the risk for certain health issues. Why is it important for brain function? While it has a bad rap in the health world, cholesterol is actually really important for your proper brain function. Your brain is the most cholesterol-rich organ in your body. Specifically, cholesterol helps make up cell membranes, including those in nerve cells, and plays a crucial role in your neurons' ability to "talk" to each other and transmit information. When cholesterol levels are out of balance, it can impact that transmission of essential information between nerve cells, leading to cognitive issues that are seen with neurodegenerative diseases like Alzheimer's disease. Cholesterol is also a building block for steroid hormones, which support brain function. However, that doesn't mean more cholesterol is always good for your brain. High levels of LDL cholesterol are usually considered a modifiable risk factor for ischemic stroke, or 'clogged pipes' in the brain, explains Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. 'There is less research and understanding on the possible benefits of cholesterol found in spinal fluid including HDL, which we classically identify as the 'good cholesterol,'' Dr. Segil says. 'We know high levels of certain types of cholesterol cause strokes and we are less clear in the year 2025 about the benefits of cholesterol in brain function.' How does this link back to Alzheimer's? This particular study noted that cholesterol found in lipoproteins were different in patients with Alzheimer's disease, but Dr. Segil says that there is a 'complicated' relationship between lipids and protein in the brain. 'Some researchers continue to assign memory loss symptoms in patients with Alzheimer's due to abnormal brain protein levels and this paper noted lipid brain levels may also be abnormal,' he says. Dr. Segil points out that neurologists commonly prescribe medications called statins to lower levels of cholesterol and the risk of stroke. Lowering levels of LDL cholesterol can decrease the risk of developing certain type of dementia, including vascular dementia, he says. But it's not clear if it may do more. 'Further research will determine if lowering your cholesterol will result in lower chances of getting Alzheimer's dementia,' he says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals Solve the daily Crossword
